Market Place
Sourcing Support
Rosen Law Urges NASDAQ:RGNX Investors with Losses to Contact Firm
14 Apr 2026 //
PHARMIWEB
REGENXBIO Announces Q4, Full-Year 2025 Results & Highlights
05 Mar 2026 //
PR NEWSWIRE
FDA Rejects REGENXBIO`s Hunter Over Control, Surrogate Issues
03 Mar 2026 //
BIOSPACE
REGENXBIO Wins Gene Therapy Patent Battle Against Sarepta
23 Feb 2026 //
BIOSPACE
Regenxbio Spotlights Catalysts, Reveals Success in Gene Therapy
11 Jan 2026 //
PR NEWSWIRE
Regenxbio Announces Presentation At The World Muscle Society
29 Sep 2025 //
PR NEWSWIRE
Regenxbio to Participate in Upcoming Investor Conferences
28 Aug 2025 //
PR NEWSWIRE
Regenxbio’s Hunter Syndrome Therapy Hit With 3-Month PDUFA Delay
20 Aug 2025 //
BIOSPACE
FDA Extends Review of Regenxbio`s RGX-121 BLA for MPS II Therapy
18 Aug 2025 //
PR NEWSWIRE
Regenxbio Launches Pivotal Program for Surabgene Lomparvovec
08 Aug 2025 //
PR NEWSWIRE
Regenxbio Shows Benefits of Microdystrophin in Duchenne Gene
11 Jul 2025 //
PR NEWSWIRE
RegenXBio Links DMD Gene Therapy to Improved Outcomes
05 Jun 2025 //
PR NEWSWIRE
Regenxbio Reports Positive Biomarker Data from Duchenne Trial
19 Mar 2025 //
PR NEWSWIRE
RegenXBio sells Hunter syndrome gene therapy commercial rights
15 Jan 2025 //
PR NEWSWIRE
FDA Endorses Speedy Approval Path for Regenxbio Duchenne Therapy
18 Nov 2024 //
BIOPHARMADIVE
Regenxbio Initiates Pivotal Phase of RGX-202 Duchenne Trial
18 Nov 2024 //
PR NEWSWIRE
REGENXBIO Reports Q3 2024 Results & Operational Updates
06 Nov 2024 //
PR NEWSWIRE
Wet AMD Gene Therapy Could Reach Millions
03 Sep 2024 //
BIOSPACE
REGENXBIO Reports Q2 2024 Results And Operational Highlights
01 Aug 2024 //
PR NEWSWIRE
REGENXBIO Announces Lancet Publication of Phase I/IIa Study of ABBV-RGX-314
28 Mar 2024 //
PR NEWSWIRE
REGENXBIO Announces Pivotal Trial of RGX-121 Achieves Primary Endpoint
07 Feb 2024 //
PR NEWSWIRE
REGENXBIO Announces Positive Data from Phase II AAVIATE® Trial of ABBV-RGX-314
16 Jan 2024 //
PR NEWSWIRE
Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Diabetic Retinopathy
06 Nov 2023 //
PRESS RELEASE
REGENXBIO Presents Positive Data from Phase II ALTITUDE® Trial of ABBV-RGX-314
03 Nov 2023 //
PR NEWSWIRE
REGENXBIO Presents Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202
03 Oct 2023 //
PR NEWSWIRE
Regenxbio, UPenn file patent suit against Sarepta related to gene therapy
29 Jun 2023 //
ENDPTS
REGENXBIO Receives FDA RMAT Designation for RGX-121 Gene Therapy
23 May 2023 //
PRESS RELEASE
REGENXBIO Announces Presentation at the Barclays Summit 2023
22 May 2023 //
PR NEWSWIRE
REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy
16 May 2023 //
PRESS RELEASE
Additional Positive Interim Data from Phase I/II Trial of REGENXBIO`S RGX-111
24 Feb 2023 //
PR NEWSWIRE
Additional Positive Data from PI/II/III CAMPSIITE Trial of REGENXBIO`s RGX-121
22 Feb 2023 //
PR NEWSWIRE
Regenxbio Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate
23 Jan 2023 //
PR NEWSWIRE
